PEDIATRICS Vol. 62 No. 2 August 1978, pp. 253
This Article
Right arrow Full Text (PDF)
Right arrow Thia Policy is No Longer Valid.
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

PUVA: A Caution

A new investigational treatment for severe psoriasis has been introduced,1,2 but it is being widely used in an uncontrolled fashion. This treatment is a form of photochemotherapy known as PUVA (psoralen with ultraviolet light in the A range) and consists of total body irradiation with high-intensity, long-wave-length, ultraviolet light of a narrow band (320 to 400 nm) after oral administration of 8-methoxypsoralen (methoxsalen).

The mechanism by which PUVA produces therapeutic results is thought to be the formation of psoralen-DNA photo adducts that decrease cellular replication in the epidermis. PUVA is known to cause mutations to mammalian cells in vitro3,4 and to produce chromosomal damage in vivo5,6; these changes in DNA have been linked experimentally to teratogenesis and carcinogenesis.